JP2023533871A5 - - Google Patents
Info
- Publication number
- JP2023533871A5 JP2023533871A5 JP2023503113A JP2023503113A JP2023533871A5 JP 2023533871 A5 JP2023533871 A5 JP 2023533871A5 JP 2023503113 A JP2023503113 A JP 2023503113A JP 2023503113 A JP2023503113 A JP 2023503113A JP 2023533871 A5 JP2023533871 A5 JP 2023533871A5
- Authority
- JP
- Japan
- Prior art keywords
- unit
- fusion polypeptide
- antigen
- expression
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20185743.0 | 2020-07-14 | ||
| EP20185743 | 2020-07-14 | ||
| EP20207526 | 2020-11-13 | ||
| EP20207526.3 | 2020-11-13 | ||
| EP21171319 | 2021-04-29 | ||
| EP21171319.3 | 2021-04-29 | ||
| PCT/EP2021/069582 WO2022013277A1 (en) | 2020-07-14 | 2021-07-14 | Apc targeting units for immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533871A JP2023533871A (ja) | 2023-08-04 |
| JP2023533871A5 true JP2023533871A5 (https=) | 2024-07-19 |
Family
ID=79555093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503113A Pending JP2023533871A (ja) | 2020-07-14 | 2021-07-14 | 免疫療法のためのａｐｃ標的化単位 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230355733A1 (https=) |
| EP (1) | EP4181949A1 (https=) |
| JP (1) | JP2023533871A (https=) |
| AU (1) | AU2021307553A1 (https=) |
| CA (1) | CA3183951A1 (https=) |
| WO (1) | WO2022013277A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023023260A2 (pt) | 2021-05-10 | 2024-01-30 | Nykode Therapeutics ASA | Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica |
| US20250304626A1 (en) | 2021-05-26 | 2025-10-02 | Evaxion Biotech A/S | Vaccination targeting intracellular pathogens |
| CN114106207B (zh) * | 2022-01-24 | 2022-04-26 | 诺未科技（北京）有限公司 | Ccl5的用途 |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1503793A2 (en) * | 2002-05-10 | 2005-02-09 | Inex Pharmaceuticals Corp. | Cancer vaccines and methods of using the same |
| AU2013224658A1 (en) * | 2006-07-21 | 2013-09-19 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| JP2013532971A (ja) * | 2010-06-25 | 2013-08-22 | バッシボディ アクスイェ セルスカプ | ホモ二量体タンパク質コンストラクト |
| AU2012311238A1 (en) * | 2011-09-23 | 2014-04-17 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| IL260030B2 (en) * | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| US20180161412A1 (en) * | 2016-12-14 | 2018-06-14 | Cyvax, Inc. | Extended protection protein vaccines against infectious agents |
| CA3060569A1 (en) | 2017-04-19 | 2018-10-25 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| WO2018201017A1 (en) * | 2017-04-27 | 2018-11-01 | Washington University | Dendritic cell targeted adenovirus for vaccination |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| CN113423419A (zh) * | 2019-01-04 | 2021-09-21 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
| US20230147574A1 (en) * | 2020-04-07 | 2023-05-11 | Evaxion Biotech A/S | Neoepitope immunotherapy with APC targeting unit |
-
2021
- 2021-07-14 CA CA3183951A patent/CA3183951A1/en active Pending
- 2021-07-14 WO PCT/EP2021/069582 patent/WO2022013277A1/en not_active Ceased
- 2021-07-14 US US18/004,889 patent/US20230355733A1/en active Pending
- 2021-07-14 JP JP2023503113A patent/JP2023533871A/ja active Pending
- 2021-07-14 EP EP21742837.4A patent/EP4181949A1/en active Pending
- 2021-07-14 AU AU2021307553A patent/AU2021307553A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533871A5 (https=) | ||
| JP2023521722A5 (https=) | ||
| JP7190528B2 (ja) | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 | |
| JP7578938B2 (ja) | Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用 | |
| US8097257B2 (en) | MAGE3 polypeptides | |
| CA2687395C (en) | Complement factor h-derived short consensus repeat-antibody constructs | |
| RU2677799C2 (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| JP2022529989A (ja) | フラジェリン融合タンパク質及びその使用 | |
| KR20190057345A (ko) | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 | |
| HU228382B1 (en) | Vaccine composition | |
| IL278418B2 (en) | Vaccine composition | |
| US11352416B2 (en) | Mosaic chimeric viral vaccine particle | |
| JP2023522588A5 (https=) | ||
| JP2023533871A (ja) | 免疫療法のためのａｐｃ標的化単位 | |
| JP2022519713A (ja) | Ｃａｒ操作されたｔ細胞およびサイトカインを含む治療 | |
| JP2023521722A (ja) | Ａｐｃ標的化単位を用いたネオエピトープ免疫療法 | |
| JP6873530B2 (ja) | 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ） | |
| WO2024222926A1 (zh) | 可自组装为纳米颗粒的融合蛋白及其在免疫中的应用 | |
| JP2006505252A (ja) | 抗原およびアジュバントの多量体複合体 | |
| AU2015330971B2 (en) | Chimeric proteins | |
| JP7585480B2 (ja) | Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原 | |
| JP2023546298A5 (https=) | ||
| Gor et al. | Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response | |
| JP2014506576A (ja) | ４−１ｂｂｌを含むアジュバント組成物 | |
| CN115197303B (zh) | 一种s蛋白的受体结合结构域的突变体及其应用 |